Adicet Bio’s third-quarter net loss narrowed year over year as operating expenses declined to $19.80 million. The company reported positive Phase 1 data for prula-cel in SLE and lupus nephritis and said its $100.9 million in cash and equivalents is expected to fund operations into the second half of 2027.
Adicet Bio reported a third-quarter net loss of $18.88 million, or $1.76 per basic share, and operating expenses of $19.80 million. Lower research and development expenses contributed to the decline in operating costs.
The company reported positive Phase 1 safety and efficacy data for prula-cel in patients with SLE and lupus nephritis. It has initiated pivotal study activities for prula-cel in lupus nephritis and Phase 1 startup for ADI-212 in prostate cancer. Cash and equivalents of $100.9 million are expected to fund operations into the second half of 2027.
Adicet Bio expects a regulatory update and 12-month follow-up data from about 22 patients in the first quarter of 2027, and anticipates Phase 1 prula-cel data in systemic sclerosis in the second quarter of 2027. The company plans to begin its first in vivo CAR-T clinical program in the second half of 2027.
